Heptares, Cubist Join On GPCR Research | Chemical & Engineering News
Volume 91 Issue 2 | p. 21 | Concentrates
Issue Date: January 14, 2013

Heptares, Cubist Join On GPCR Research

Department: Business
Keywords: G protein-coupled receptors, partnership, drug discovery, drug development

Heptares Therapeutics and Cubist Pharmaceuticals will collaborate on the discovery of new therapies targeting G protein-coupled receptors (GPCRs) using Heptares’ drug discovery platform. Under the agreement, Cubist will hold exclusive worldwide rights to develop and commercialize drug candidates identified by the partners. Cubist will pay Heptares $5.5 million up front and up to $4 million in research funding, plus milestones and royalties, for the first drug target. GPCRs are membrane proteins involved in a broad range of biological processes and diseases.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment